Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...
Moleculin Biotech, Inc. is a clinical stage pha...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...
We are Anchiano Therapeutics, a pivotal-stage b...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
Join the National Investor Network and get the latest information with your interests in mind.